Registry update — unassessed
A Phase 1b, Multi-cohort Clinical Trial Assessing Safety and Feasibility of Exercise and Spermidine Administered in Conjunction With Lamivudine (RTi) or Rapamycin (mTORi) to Assess Impact on Dynamic Changes of Inflammation and Aging
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
RCTMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 27, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Research update
What it does not prove
- The trial was designed to assess feasibility and safety, not efficacy; no evidence is presented that the intervention affects inflammation, aging, or lifespan. Phase 1b trials in small populations do not establish that benefits would generalize to broader populations or persist long-term.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- Safety and feasibility of combined exercise, spermidine supplementation, and rapamycin or lamivudine
- Effect size
- —
- Significance
- Not reported
- Journal
- Icahn School of Medicine at Mount Sinai
- Published
- Aug 27, 2026
Sources
Primary source
- Icahn School of Medicine at Mount Sinai ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 2. This is not a claim of full-text review.
This is a study assessing the feasibility of performing an anti-aging intervention which is a combination of an exercise regimen, spermidine supplementation, and either rapamycin or lamivudine.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.